Source: Annual Congress 2013 –Pulmonary circulation: basic science
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. Ricard, L. Tu, A. Huertas, C. Phan, M. Le Hiress, E. Fadel, M. Humbert, C. Guignabert (Le Plessis-Robinson, Le Kremlin-Bicêtre, France). LATE-BREAKING ABSTRACT: Evidence for a critical contribution of pericytes in pulmonary arterial hypertension pathogenesis. Eur Respir J 2013; 42: Suppl. 57, 1497

Member's Comments

No comment yet.

Related content which might interest you: LATE-BREAKING ABSTRACT: TNFalpha mediates ectodomain shedding of BMPR-II: A potential role in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: basic science Year: 2013 LATE-BREAKING ABSTRACT: KCNK3 dysfunction contributes to the development of pulmonary arterial hypertension – Characterization of Kcnk3 deficient rats Source: International Congress 2016 – Pulmonary hypertension: novel insights Year: 2016 MIF/CD74 contributes to the endothelial pro-inflammatory phenotype in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: basic science Year: 2013 mir-126 contribute to angiogenesis defect in pulmonary arterial hypertension right ventricle failure Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Analysis of pulmonary endothelial microparticles, haemodynamics and functional class in pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 Inflammatory mediators contribute to pulmonary arterial cell dysfunction in a pulmonary arterial hypertension patient with BMPR2 mutation Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 Immunity in idiopathic pulmonary arterial hypertension (IPAH), a role for activated DCs? Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 LATE-BREAKING ABSTRACT: Riociguat for the treatment of pulmonary arterial hypertension (PAH): 2-year results from the PATENT-2 long-term extension Source: International Congress 2014 – New technologies and biomarkers in lung disease Year: 2014 Peripheral arterial stiffness and endothelial dysfunction in pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: the right ventricle and its load Year: 2015 Novel treatment for pulmonary vascular disease: lessons from pathophysiology Source: Annual Congress 2006 - Molecular pathology: an approach to lung diseases Year: 2006 Endothelial dysfunction in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension Year: 2016 Endothelial CFTR dysfunction and its involvement in the pathogenesis of pulmonary arterial hypertension Source: Eur Respir J, 58 (2) 2101645; 10.1183/13993003.01645-2021 Year: 2021 LATE-BREAKING ABSTRACT: The bromodomain-containing protein 4: the epigenetic origin of the oncogenic signature in pulmonary hypertension Source: International Congress 2014 – New technologies and biomarkers in lung disease Year: 2014 Endothelial NO and its pathophysiologic regulation Source: Annual Congress 2007 - Role of the endothelium in pulmonary function and disease Year: 2007 Pulmonary hypertension: the science behind the disease spectrum Source: Eur Respir Rev 2012; 21: 19-26 Year: 2012 Time-resolved study of endothelial shear-responsiveness in pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015 Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension Source: Eur Respir J, 58 (5) 2000653; 10.1183/13993003.00653-2020 Year: 2021 Pulmonary vessels remodeling in COPD Source: International Congress 2016 – Pulmonary hypertension in lung disease Year: 2016 Unique characteristics of patients with pulmonary arterial hypertension associated with congenital heart disease compared to the rest of pulmonary arterial hypertension subgroups Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 LATE-BREAKING ABSTRACT: Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 2-year results from the CHEST-2 long-term extension Source: International Congress 2014 – New technologies and biomarkers in lung disease Year: 2014